Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Lymphoma, Non-Hodgkin 8Lymphoma, Follicular 8Lymphoma 7Lymphoma, Large B-Cell, Diffuse 6Lymphoma, B-Cell, Marginal Zone 5Recurrence 4Myeloproliferative Disorders 4Lymphoma, Mantle-Cell 4Primary Myelofibrosis 3Hereditary Sensory and Autonomic Neuropathies 2Breast Neoplasms 2Advanced Malignancies 2Unresectable or Metastatic Solid Tumors 1Triple Negative Breast Neoplasms 1Solid Tumors 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, B-Cell 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Cyclophosphamide 65Peripheral Blood Stem Cell Transplantation 37fludarabine phosphate 36Doxorubicin 31Etoposide 30Vincristine 29Whole-Body Irradiation 28Rituximab 26Prednisone 26Brentuximab Vedotin 26Mycophenolic Acid 25Filgrastim 22Cyclosporine 22Methotrexate 20Busulfan 19Cytarabine 18Radiotherapy 17Antilymphocyte Serum 16Tacrolimus 15Melphalan 15Carboplatin 14Ifosfamide 13Bortezomib 13Methylprednisolone 12Gemcitabine 11Flow Cytometry 10Lenalidomide 9Dexamethasone 9romidepsin 8Vorinostat 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Large-Cell, Anaplastic × parsaclisib × Clear all
NCT04774068 2025-01-17

Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
5 enrolled
DermatologicLymphoid

Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡